本文为加密货币新手全方位解析如何购买以太坊(ETH)，涵盖选择标准、Binance、Coinbase、Kraken、OKX及 Bitget五大平台的深度客观对比。并附赠详细的Bitget手把手购买教程与安全存储指南，助您安全、低成本地开 启ETH投资之旅。 为什么以太坊(ETH)是新手的核心资产配置？ 以太坊远超其货币属性，它是智能合约和去中心化应用（DApps）的基础平台，构建了整个DeFi、NFT和元宇 宙的生态基石。对于新手而言，选择首项加密货币投资时，资产的稳定性、认知度、生态价值和长期增长潜力 至关重要。以太坊(ETH)在这四个方面展现了全面的综合优势，远不止是一种数字货币，更是参与未来互联网 （Web3）的"基础层股票"。 1. 强大的历史表现：经过验证的增值资产 尽管过去表现不能代表未来，但历史数据是衡量资产生命力和市场信心的关键指标。自2015年诞生以来，ETH 为早期投资者带来了巨额回报。更重要的是，它展现了穿越牛熊周期的韧性，屡次从市场低谷中复苏并创下新 高。这种经过验证的长期上涨趋势，为其作为"核心配置"的地位提供了坚实的数据支撑。 长期回报视角：即便从上一轮牛市高点（2021年11月， ...

Core Viewpoint - Citigroup predicts Ethereum's year-end target price at $4,300, which is lower than the current spot price, based on a model considering fundamental value, capital inflow potential, and macroeconomic environment [1][15]. Group 1: Value Capture and L2 Challenges - The report highlights that Ethereum's value is closely tied to its network activity as a smart contract platform, unlike Bitcoin's "digital gold" positioning [1]. - Recent growth in Ethereum's ecosystem activity is primarily occurring on Layer 2 (L2) networks, raising concerns about how much value L2 can translate back to the Ethereum mainnet [3]. - Citigroup assumes a 30% value transmission rate from L2 activities to the Ethereum mainnet, indicating that even with this assumption, Ethereum's current price exceeds the valuation derived from combined Layer 1 (L1) and L2 activities [3]. Group 2: Fundamental Value and Price Risks - Citigroup's model suggests that Ethereum's current price is above what its network activity can support, likely driven by recent ETF inflows and market excitement over tokenization use cases, indicating a risk of overvaluation in the short term [4]. - The report notes that while the inflow of funds into Ethereum ETFs can significantly impact prices (with every $1 billion inflow potentially raising prices by 6%), the overall inflow is expected to be much lower than that of Bitcoin [4][10]. Group 3: Macroeconomic Environment - The macroeconomic environment has a limited impact on Ethereum's price in the base case scenario, although it could become a key driver in a recession, particularly if the stock market declines [11][14]. - Citigroup's baseline scenario predicts a year-end price of $4,300, assuming moderate capital inflows and sustained market excitement about Ethereum's network use cases [15]. Group 4: Price Scenarios - In a bullish scenario, the price could reach $6,400, driven by significant increases in network activity and sustained demand from ETFs and treasury companies [15]. - Conversely, in a bearish scenario, the price could drop to $2,200, primarily influenced by macroeconomic factors such as a recession and stock market downturns [15]. Group 5: Overall Analysis Framework - The report provides a clear analytical framework for investors, affirming Ethereum's value as an application platform while pointing out its core shortcoming in capturing value from the L2 ecosystem [18].

Core Viewpoint - Yunfeng Financial (00376) has entered a strategic partnership with Ant Digital Technology, focusing on the tokenization of real-world assets (RWA) through a new Layer 1 blockchain called Pharos [1] Group 1: Strategic Developments - On September 1, Yunfeng Financial announced a strategic cooperation agreement with Ant Digital Technology [1] - The company plans to invest strategically in the Pharos blockchain, which is dedicated to RWA tokenization [1] Group 2: Financial Investments - On September 2, Yunfeng Financial's board approved the purchase of 10,000 Ethereum (ETH) as a strategic reserve asset, with a total investment cost of $44 million, sourced from internal cash reserves [1] - The acquisition of ETH aims to support the company's initiatives in Web3, RWA tokenization, digital currency, ESG zero-carbon assets, and artificial intelligence [1] Group 3: Future Directions - The collaboration with Ant Digital Technology will leverage the Pharos high-performance blockchain platform to explore compliance and expansion in RWA tokenization and next-generation internet (Web3) [1] - The company is also looking into the application scenarios of ETH within its insurance business [1]

Group 1 - The company reported a revenue of RMB 1.27 billion for the first half of 2025, with distribution business revenue accounting for RMB 1.177 billion, representing 92.7% of total revenue [1] - The company has established a large distribution network covering 31 provinces, municipalities, and autonomous regions in China, with 236 direct clients and 1,073 distributors as of June 30, 2025 [1] - The company aims to leverage the high growth potential of the IVD market by diversifying product categories, expanding brand coverage, and enhancing its distribution network and hospital reach [1] Group 2 - The company has entered into a global strategic cooperation framework agreement with HashKey Group, marking a significant milestone in the integration of blockchain finance and medical innovation [2] - This collaboration will utilize HashKey's compliant trading platform and global liquidity network to assist the company in executing large-scale Ethereum (ETH) transactions and optimizing over-the-counter trading costs [2] - The partnership aims to quickly establish and expand a "Global Enhanced Ethereum Vault," improving capital efficiency and providing reliable support for future tokenization research and development projects [2]

Core Viewpoint - The company, Huajian Medical (1931.HK), has proposed to seek shareholder approval for a purchase authorization to invest in cryptocurrencies, particularly Ethereum (ETH), as part of its asset allocation strategy and business development plans [1] Group 1: Company Actions - The company's board believes that purchasing and holding cryptocurrencies is a crucial step in solidifying its Ethereum reserves and accelerating the development of the ivd.xyz exchange ecosystem [1] - The board has recommended that shareholders approve a resolution allowing the company to potentially purchase cryptocurrencies over a period of 36 months, with a total purchase limit not exceeding 3 billion HKD [1] Group 2: Strategic Alignment - The potential cryptocurrency purchases and the authorization for such purchases are considered to align with the company's long-term development strategy and the overall interests of its shareholders [1]

Core Viewpoint - The company, Huajian Medical (01931), is seeking shareholder approval to authorize the board to purchase cryptocurrencies as part of its asset allocation strategy, specifically to strengthen its Ethereum (ETH) reserves and accelerate the development of the ivd.xyz exchange ecosystem [1] Group 1 - The board believes that purchasing and holding cryptocurrencies is a crucial step for the company's business layout and development [1] - The proposed authorization for cryptocurrency purchases will be valid for a period of 36 months from the date of approval at the special shareholder meeting [1] - The total amount allocated for cryptocurrency purchases will not exceed HKD 3 billion [1]

Group 1 - The company, Huajian Medical (01931.HK), announced a voluntary plan to purchase cryptocurrency, specifically aiming to strengthen its Ethereum (ETH) reserves and accelerate the development of the ivd.xyz exchange ecosystem [1][2] - The board of directors seeks shareholder approval to grant purchasing authority for potential cryptocurrency acquisitions, with a total purchase limit not exceeding HKD 3 billion over a period of 36 months [1][2] - The board believes that the potential cryptocurrency purchases align with the company's long-term development strategy and overall shareholder interests, providing necessary flexibility to capture opportunities in a rapidly changing market [2] Group 2 - Ethereum (ETH), launched in 2014, is the second-largest cryptocurrency by market capitalization, following Bitcoin [2] - The authorization for purchasing cryptocurrency is seen as a crucial component of the company's asset allocation strategy, aimed at building a global intellectual property trading hub for innovative drugs and supporting the international expansion of national innovative drugs [2] - The company emphasizes its long-term vision of benefiting the country, the public, and the world through these strategic initiatives [2]

Core Viewpoint - The company, Huajian Medical (01931), is seeking shareholder approval to authorize the board to purchase cryptocurrencies as part of its asset allocation strategy, particularly to strengthen its Ethereum (ETH) reserves and accelerate the development of the ivd.xyz exchange ecosystem [1] Group 1 - The board believes that purchasing and holding cryptocurrencies is a crucial step for the company's business layout and development [1] - The proposed authorization for cryptocurrency purchases will be valid for a period of 36 months from the date of the special resolution passed by shareholders [1] - The total amount allocated for cryptocurrency purchases will not exceed HKD 3 billion [1]

Core Viewpoint - 华检医疗 has signed a global strategic cooperation framework agreement with HashKey Group to enhance its digital asset services and accelerate the implementation of its "Global Enhanced Ethereum (ETH) Treasury" strategy [1] Group 1: Company Developments - 华检医疗's stock price surged over 20%, reaching a new high of 9.48 HKD during trading, and is currently up 15.05% at 9.02 HKD with a trading volume of 7.94 million HKD [1] - The cooperation aims to provide more efficient, secure, and compliant digital asset services to both parties' global clients [1] Group 2: Strategic Partnership - The framework agreement will leverage HashKey Group's fully licensed compliance ecosystem to offer one-stop digital asset management services [1] - Services include large-scale trading execution and cost optimization for Ethereum (ETH), global market liquidity support, and exploring the integration of crypto asset reserves with real-world assets, particularly in medical innovation intellectual property [1] - This partnership will enable 华检医疗 to manage its Ethereum (ETH) reserves more efficiently, optimize trading costs, and access broader market resources and technical support globally [1]

Core Viewpoint - The company has officially launched a strategic upgrade to create a "Global Enhanced Ethereum (ETH) Treasury" with a focus on medical innovation and asset tokenization [1][2]. Group 1: Strategic Overview - The company aims to integrate Ethereum (ETH) as a core reserve asset to enhance the efficiency of medical innovation drug development and asset allocation [3][7]. - The new "ivd.xyz" exchange will focus on high-tech assets in global medical innovation, facilitating the tokenization of real-world assets (RWA) [1][2]. Group 2: Mechanisms and Protection Strategies - The board has authorized the management to establish a "verifiable, executable, and quantifiable" seven-layer protection mechanism to safeguard shareholders and RWA holders [5]. - Additional strategies include a "three-layer enhancement engine" to transform ETH assets from passive holding to active income generation and reinvestment [5][6]. Group 3: Market Context and Trends - The strategic move aligns with global trends in cryptocurrency asset allocation, particularly among institutional investors, and responds to regulatory frameworks in regions like Hong Kong and the U.S. [4][6]. - The company has drawn insights from leading practices in the cryptocurrency asset reserve field, referencing successful models from various global firms [6][7].